Compare Gilead Sciences, Inc. (GILD) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wolfspeed Inc — how do they compare? Gilead Sciences, Inc. trades at $134.53 (market cap $163.51B), while Wolfspeed Inc trades at $30.72 (market cap $1.82B). The key difference: Gilead Sciences, Inc. is far larger — about 89.8× Wolfspeed Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals.
| GILD | WOLF | |
|---|---|---|
Market Cap | $163.51B | $1.82B |
Sector | Health | Technology |
52-Week High | $155.80 | $73.68 |
52-Week Low | $108.22 | $1.19 |
Enterprise Value | $178.05B | $2.48B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Wolfspeed (WOLF) stock trades at $33.10, down 3.55% on the day, reflecting ongoing volatility in the semiconductor sector. The company shows mixed earnings performance with recent beats but significant losses, as evidenced by a -79.83% net income margin. Technical indicators are bearish overall, with the stock trading below its pivot point of $35 and near support at $33. Recent business developments include a strategic pivot toward high-margin defense and data center markets, a patent lawsuit against Navitas Semiconductor, and a collaboration with GE Aerospace on silicon carbide technology.
The investment outlook for Wolfspeed hinges on its successful execution of a strategic pivot from EV market headwinds to higher-growth AI data center and defense applications. While analyst sentiment is mixed with a 31.58% buy rating, the company's deep losses, negative profitability metrics, and competitive litigation risks present significant challenges. Upside potential exists if recent partnerships and technology launches translate to improved financial performance and margin expansion in coming quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
